Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

Basit Öğe Kaydı
dc.authoridSahin, Elif/0000-0002-1976-3951
dc.authoridBayramgil, Ayberk/0000-0003-1782-7808
dc.authoridAkbas, Sinem/0000-0002-7197-211X
dc.authoridASLAN, FERIT/0000-0002-9153-6921
dc.authoridsekmek, serhat/0000-0003-4650-248X
dc.authoridmajidova, nargiz/0000-0002-2575-5819
dc.authoridBayram, Ertugrul/0000-0001-8713-7613
dc.contributor.authorSekmek, Serhat
dc.contributor.authorOzsan celebi, Sema Nur
dc.contributor.authorBayram, Dogan
dc.contributor.authorErol, Cihan
dc.contributor.authorKos, Fahriye Tugba
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorAltintas, Yunus Emre
dc.date.accessioned2025-02-22T14:08:59Z
dc.date.available2025-02-22T14:08:59Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractWe aimed to compare FOLFIRI and bevacizumab with FOLFIRI and aflibercept in terms of overall survival (OS), progression-free survival (PFS) and safety in patients with RAS-mutant metastatic colon cancer who progressed after first-line FOLFOX or XELOX and bevacizumab treatment. This retrospective study included 243 patients from 15 different centres in Turkey. The endpoints of the study were OS, PFS and safety and side effect outcomes. The median age of the patients included in the study was 60 (21-85) years. Of the patients enrolled in the study, 114 patients (46.9%) received aflibercept and 129 patients (53.1%) received bevacizumab. Median OS was 11.2 (95% CI: 9.1-13.2) months in patients receiving FOLFIRI + aflibercept and 14.1 (95% CI: 11.2-17.1) months in patients receiving FOLFIRI + bevacizumab. The median PFS was 5.7 (95% CI: 4.9-6.5) months in the aflibercept arm and 7.7 (95% CI: 7.1-8.3) months in the bevacizumab arm. Grade 3-4 side effects were observed in 58 (50.9%) patients in the aflibercept arm and 33 (25.6%) patients in the bevacizumab arm. As a result of our study, in patients with metastatic RAS-mutant colon cancer who progressed after first-line oxaliplatin-based doublet chemotherapy and bevacizumab, better OS and PFS results were obtained in patients receiving bevacizumab with FOLFIRI compared to patients receiving aflibercept with FOLFIRI. In addition, the side effect profile was more tolerable in the bevacizumab arm.en_US
dc.identifier.doi10.1038/s41598-024-81371-5
dc.identifier.issn2045-2322
dc.identifier.issue1en_US
dc.identifier.pmid39616250en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1038/s41598-024-81371-5
dc.identifier.urihttps://hdl.handle.net/11468/29740
dc.identifier.volume14en_US
dc.identifier.wosWOS:001367885500041
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherNature Portfolioen_US
dc.relation.ispartofScientific Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectMetastatic colon canceren_US
dc.subjectAflibercepten_US
dc.subjectBevacizumaben_US
dc.subjectReal-life dataen_US
dc.titleBevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu